Diabetes is the common term for several metabolic disorders in which the body no longer produces insulin or uses the insulin it produces ineffectively.
It is a common condition and is characterised by abnormally high blood sugar levels.
Novo Nordisk's commitment to the worldwide haemophilia community has made available an innovative and effective treatment for haemophilia patients with inhibitors.
Read more about Haemostasis management
Human growth hormone (hGH) is a biosynthetic hormone replacement therapy.
It is 100% identical to the natural growth hormone produced by the body and must be injected in order to work properly.
Read more about Growth hormone therapy
The decline in oestrogen during menopause is responsible for common symptoms like hot flushes and vaginal dryness.
Read more about Hormone replacement therapy
Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries.
 | Novo Nordisk in the USA |
 | Novo Nordisk in Denmark |
Or choose:
